Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)

NCT04614337 is registered in ClinicalTrials.gov with Lumos Pharma as lead sponsor.

NCT NCT04614337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
Lead sponsor
Lumos Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2020
Completion date
September 4, 2024
Enrollment
104 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency